Biotechnology Alexion Pharmaceuticals today announced that positive results from one of the two large Phase III studies of ALXN1210, the company’s investigational long-acting C5 complement inhibitor, in patients with paroxysmal nocturnal hemoglobinuria (PNH) were selected for presentation during the late-breaking oral session on June 17, 2018 at the Annual Conference of the European Hematology Association (EHA) in Stockholm, Sweden. 15 June 2018